All In Biotech

Drug Trial Radar · NCT03414658

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

100

Actual

Start

Jun 21, 2018

Primary completion

May 1, 2023

Study completion May 31, 2027

Sponsor

Lead sponsor
Adrienne G. WaksAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer; Breast Cancer Research Foundation; Johns Hopkins University
First posted
Jan 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)

Conditions

  • Breast Cancer

Interventions

  • VinorelbineDrug

    work by interfering with cell division, which leaves the tumor unable to grow and spread

  • TrastuzumabDrug

    trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.

  • AvelumabDrug

    monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein

  • UtomilumabDrug

    Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: 2 years

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California San Francisco

    San Francisco, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • University of Chicago Medical Center

    Chicago, Illinois

  • Indiana University Health Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Johns Hopkins University

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • University of Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Washington Fred Hutchinson Cancer Care

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.